Sugi Predict

Sugi Predict / Compounds / Pyridine

Pyridine

Pyridine

SCHEMBL6531369

COc1ccccc1C(Cl)(c1ccccc1)c1ccccc1OC.c1ccncc1

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 3/20 0.42
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA4 P22748 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ CA14 Q9ULX7 1/20 0.38
▸ KCNA5 P22460 7/20 0.36
▸ CASR P41180 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ NR3C2 P08235 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221587 0.90 CA1 (0.46) CYP19A1CA12CA1CA2CA4
SCHEMBL221217 0.86 CA1 (0.46) CYP19A1CA12CA1CA2CA4
Pyridine SCHEMBL6531371 0.85 KDM4E (0.40) CYP19A1KCNA5ALDH1A1SMN1; SMN2
SCHEMBL2445298 0.78 CA1 (0.55) CA12CA1CA2CA4CA7
Pyridine SCHEMBL2907844 0.77 AHR (0.47) CYP19A1CA4SMN1; SMN2HTT
Chlorotriphenylmethane SCHEMBL3638985 0.76 CYP19A1 (0.53) CYP19A1KCNA5ALDH1A1
SCHEMBL11862713 0.75 CA1 (0.46) CYP19A1CA12CA1CA2CA4
Styrene SCHEMBL7259237 0.75 ALDH1A1 (0.42) CA12CA1CA2CA4CA7
SCHEMBL221588 0.73 NFE2L2 (0.42) CA12CA1CA2CA4CA7
SCHEMBL30388593 0.73 NFE2L2 (0.42) CA12CA1CA2CA4CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050074771-A1 Carbamate-derivatized nucleosides and oligonucleosides ISIS PHARMACEUTICALS, INC. 2005-04-07 — — US disclosed
US-6803198-B2 COMPOUND FOR USE IN HUMAN THERAPEUTICS AND DIAGNOSTICS ISIS PHARMACEUTICALS, INC. 2004-10-12 — — US disclosed
US-6660720-B2 Targeted oligonucleotide conjugates ISIS PHARMACEUTICALS, INC. 2003-12-09 — — US disclosed
US-20030166896-A1 Base-modified enzymatic nucleic acid RIBOZYME PHARMACEUTICALS, INC. 2003-09-04 — — US disclosed
US-20030130220-A1 Targeted oligonucleotide conjugates IONIS PHARMACEUTICALS, INC. 2003-07-10 — — US disclosed
US-6528639-B2 Active ribozyme RIBOZYME PHARMACEUTICALS, INC. 2003-03-04 — — US disclosed
US-20030039977-A1 Carbamate-derivatized nucleosides and oligonucleosides ISIS PHARMACEUTICALS, INC. 2003-02-27 — — US disclosed
US-6525031-B2 Complexes carry primary moieties, chiefly therapeutic, to target cells; feature cell surface receptor ligands to provide specificity; ligands are preferably bound to primary moieties through polyfunctional manifold compounds. ISIS PHARMACEUTICALS, INC. 2003-02-25 — — US disclosed
US-20020058639-A1 Targeted oligonucleotide conjugates ISIS PHARMACEUTICALS, INC. 2002-05-16 — — US disclosed
US-6322987-B1 FOR TREATING AN ANIMAL HAVING A DISEASE CHARACTERIZED BY UNDESIRED PRODUCTION OF PROTEIN ISIS PHARMACEUTICALS, INC. 2001-11-27 — — US disclosed
EP-0983291-A1 CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES ISIS PHARMACEUTICALS, INC. (US) 2000-03-08 — — EP disclosed
WO-1999065925-A1 TARGETED OLIGONUCLEOTIDE CONJUGATES ISIS PHARMACEUTICALS, INC. (US) 1999-12-23 — — WO disclosed
US-5891684-A RIBOZYMES RIBOZYME PHARMACEUTICALS, INC. (US) 1999-04-06 — — US disclosed
US-5879938-A RIBOZYME WITH INCREASED ACTIVITY BY SUBSTITUTION OF MODIFIED NUCLEOTIDE INTO SUBSTRATE BINDING ARM OR CATALYTIC CORE RIBOZYME PHARMACEUTICALS, INC. (US) 1999-03-09 — — US disclosed
US-5767263-A Base-modified enzymatic nucleic acid RIBOZYME PHARMACEUTICALS, INC. (US) 1998-06-16 — — US disclosed
WO-1998011123-A1 CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES ISIS PHARMACEUTICALS, INC. (US) 1998-03-19 — — WO disclosed
EP-0799313-A2 METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES RIBOZYME PHARMACEUTICALS, INC. (US) 1997-10-08 — — EP disclosed
US-5672501-A Base-modified enzymatic nucleic acid RIBOZYME PHARMACEUTICALS, INC. (US) 1997-09-30 — — US disclosed
US-5672511-A Base-modified enzymatic nucleic acid RIBOZYME PHARMACEUTICALS, INC. (US) 1997-09-30 — — US disclosed
WO-1996018736-A2 METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES RIBOZYME PHARMACEUTICALS, INC. (US) 1996-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130220-A1 Targeted oligonucleotide conjugates CD47, CD44, FOLR1 CYP19A1 3973/4885CA12 751/4885CA1 1770/4885
US-20050074771-A1 Carbamate-derivatized nucleosides and oligonucleosides RNGTT, NUDT21, DUT CYP19A1 1140/4885CA12 1208/4885CA1 1504/4885
US-20030039977-A1 Carbamate-derivatized nucleosides and oligonucleosides RNGTT, NUDT21, DUT CYP19A1 1140/4885CA12 1208/4885CA1 1504/4885
US-20020058639-A1 Targeted oligonucleotide conjugates CD47, CD44, FOLR1 CYP19A1 3973/4885CA12 751/4885CA1 1770/4885
US-20030166896-A1 Base-modified enzymatic nucleic acid RNASE1, RNGTT, RNASEL CYP19A1 3310/4885CA12 1057/4885CA1 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.